Biocon reports on its revenues from biosimilars and the FDA status of its insulin glargine product.
In an update on the possibility of an interchangeable designation for its insulin glargine biosimilar candidate (Semglee), Biocon of Bengaluru, India, said in an earnings statement this week that an “end of July 2021” FDA decision is possible.
The much-anticipated interchangeable designation could potentially be the first awarded for a biosimilar, which is a copy biologic that has no clinically meaningful differences from the originator, or reference, product. The interchangeable designation would allow pharmacists to substitute the insulin product for the reference product (Lantus) without the express authorization of the prescribing physician.
In August 2020, Biocon Biologics and Mylan (now Viatris), launched Semglee on the US market but did not have biosimilar or interchangeable status for it because it wasn’t approved under the biosimilar pathway in the Biologics Price Competition and Innovation Act (BPCIA). They have since sought biosimilar and interchangeable status for this product. Biocon Biologics is a subsidiary of Biocon.
Potentially, these designations would help to build acceptance and use of this product in the medical community, leading to increased revenues and, if the product helps to lower the cost of insulin, broader access to this medicine for patients who currently have difficulty paying for it.
“The regulatory process for the grant of ‘interchangeability’ designation to our [glargine; Semglee] is progressing under the 351(k) pathway in the United States,” Biocon said. Biologics license applications for biosimilar and interchangeable status must be submitted under the 351(k) pathway of the Public Health Service Act, which encompasses the BPCIA.
Insulin Aspart Candidate
In addition, Biocon has submitted an application to the FDA for a biosimilar form of insulin aspart. Whereas glargine is a “long-acting” insulin, aspart takes effect in the body with rapidity and is considered “short-acting.”
The company said there are no pending requirements from the FDA for technical or clinical information about the aspart biosimilar candidate and the FDA has scheduled a “pre-approval inspection” of Biocon’s manufacturing facility in Malasia, where the insulin aspart would be manufactured. That inspection would occur in the final business quarter of this year, Biocon said.
Total revenue was up for the year just ended but total profits were down at Biocon. The company said biosimilar revenues have grown and highlighted those as a growth driver.
Profit and Loss
Biocon Biologics reported $102 million in revenues for the quarter just ended, up from $93 million in the comparable year-ago quarter, representing a 10% increase. These figures include biosimilar revenues predominantly, but also sales of novel biologics marketed in India. Biocon's net profit for the just-ended quarter was $11.3 million vs $20 million a year earlier, down 44%. Generics income for the company was down 22%.
The company attributed the decline in profits partly to losses associated with Bicara Therapeutics, a start-up novel drug development subsidiary based in Boston, Massachusetts; as well as COVID-19–related operational challenges for the company’s facilities in Bengaluru and Hyderabad, which produce key ingredients for drugs, known as active pharmaceutical ingredients, or APIs.
“Globally, we see a strong demand for biosimilars and generic drugs, given the growing emphasis on affordable drug pricing,” company officials said in their earnings statement.
Read about expert opinion on the potential for competition in the insulin market here.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.